|
1
|
Yoshizawa, Hayashi H, Tashiro Y, Sakawa S,
Moriwaki H, Akimoto T, Doi O, Kimura M, Kawarasaki Y, Inoue K and
Itoh K: Effect of VKORC1-1639 G>A polymorphism, body weight,
age, and serum albumin alterations on warfarin response in japanese
patients. Thromb Res. 124:161–166. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kidane AG, Burriesci G, Cornejo P, Dooley
A, Sarkar S, Bonhoeffer P, Edirisinghe M and Seifalian AM: Current
developments and future prospects for heart valve replacement
therapy. J Biomed Mater Res B Appl Biomater. 88:290–303. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Glurich I, Burmester JK and Caldwell MD:
Understanding the pharmacogenetic approach to warfarin dosing.
Heart Fail Rev. 15:239–248. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Arellano-Rodrigo E: Home monitoring of
warfarin effects. N Engl J Med. 364:378–379. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Inui M, Martello G and Piccolo S: MicroRNA
control of signal transduction. Nat Rev Mol Cell Biol. 11:252–263.
2010. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen CZ, Li L, Lodish HF and Bartel DP:
MicroRNAs modulate hematopoietic lineage differentiation. Science.
303:83–86. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Poy MN, Hausser J, Trajkovski M, Braun M,
Collins S, Rorsman P, Zavolan M and Stoffel M: miR-375 maintains
normal pancreatic alpha-and beta-cell mass. Proc Natl Acad Sci USA.
106:5813–5818. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hornstein E, Mansfield JH, Yekta S, Hu JK,
Harfe BD, McManus MT, Baskerville S, Bartel DP and Tabin CJ: The
microRNA miR-196 acts upstream of Hoxb8 and Shh in limb
development. Nature. 438:671–674. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Borel C and Antonarakis SE: Functional
genetic variation of human miRNAs and phenotypic consequences. Mamm
Genome. 19:503–509. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Saetrom P, Biesinger J, Li SM, Smith D,
Thomas LF, Majzoub K, Rivas GE, Alluin J, Rossi JJ, Krontiris TG,
et al: A risk variant in an miR-125b binding site in BMPR1B is
associated with breast cancer pathogenesis. Cancer Res.
69:7459–7465. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ryan BM, Robles AI and Harris CC: Genetic
variation in microRNA networks: The implications for cancer
research. Nat Rev Cancer. 10:389–402. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gamazon ER, Ziliak D, Im HK, LaCroix B,
Park DS, Cox NJ and Huang RS: Genetic architecture of microRNA
expression: Implications for the transcriptome and complex traits.
Am J Hum Genet. 90:1046–1063. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sridharan K, Modi T, Bendkhale S, Kulkarni
D, Gogtay NJ and Thatte UM: Association of genetic polymorphisms of
CYP2C9 and VKORC1 with bleeding following warfarin: A case-control
study. Curr Clin Pharmacol. 11:62–68. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Warburton A, Breen G, Bubb VJ and Quinn
JP: A GWAS SNP for schizophrenia is linked to the internal MIR137
promoter and supports differential Allele-Specific expression.
Schizophr Bull. 42:1003–1008. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rieder MJ, Reiner AP, Gage BF, Nickerson
DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL and
Rettie AE: Effect of VKORC1 haplotypes on transcriptional
regulation and warfarin dose. N Engl J Med. 352:2285–2293. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
D'Andrea G, D'Ambrosio RL, Di Perna P,
Chetta M, Santacroce R, Brancaccio V, Grandone E and Margaglione M:
A polymorphism in the VKORC1 gene is associated with an
interindividual variability in the dose-anticoagulant effect of
warfarin. Blood. 105:645–649. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shomron N: MicroRNAs and pharmacogenomics.
Pharmacogenomics. 11:629–632. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Peréz-Andreu V, Teruel R, Corral J, Roldán
V, García-Barberá N, Salloum-Asfar S, Gómez-Lechón MJ, Bourgeois S,
Deloukas P, Wadelius M, et al: miR-133a regulates vitamin K
2,3-epoxide reductase complex subunit 1 (VKORC1), a key protein in
the vitamin K cycle. Mol Med. 18:1466–1472. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ainle FN, Mumford A, Tallon E, McCarthy D
and Murphy K: A vitamin K epoxide reductase complex subunit 1
mutation in an Irish patient with warfarin resistance. Ir J Med
Sci. 177:159–161. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yuan HY, Chen JJ, Lee MT, Wung JC, Chen
YF, Charng MJ, Lu MJ, Hung CR, Wei CY, Chen CH, et al: A novel
functional VKORC1 promoter polymorphism is associated with
inter-individual and inter-ethnic differences in warfarin
sensitivity. Hum Mol Genet. 14:1745–1751. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang D, Chen H, Momary KM, Cavallari LH,
Johnson JA and Sadée W: Regulatory polymorphism in vitamin K
epoxide reductase complex subunit 1 (VKORC1) affects gene
expression and warfarin dose requirement. Blood. 112:1013–1021.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kealey C, Chen Z, Christie J, Thorn CF,
Whitehead AS, Price M, Samaha FF and Kimmel SE: Warfarin and
cytochrome P450 2C9 genotype: Possible ethnic variation in warfarin
sensitivity. Pharmacogenomics. 8:217–225. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schelleman H, Chen Z, Kealey C, Whitehead
AS, Christie J, Price M, Brensinger CM, Newcomb CW, Thorn CF,
Samaha FF and Kimmel SE: Warfarin response and vitamin K epoxide
reductase complex 1 in African Americans and Caucasians. Clin
Pharmacol Ther. 81:742–747. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kimmel SE, Christie J, Kealey C, Chen Z,
Price M, Thorn CF, Brensinger CM, Newcomb CW and Whitehead AS:
Apolipoprotein E genotype and warfarin dosing among Caucasians and
African Americans. Pharmacogenomics J. 8:53–60. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Loebstein R, Dvoskin I, Halkin H, Vecsler
M, Lubetsky A, Rechavi G, Amariglio N, Cohen Y, Ken-Dror G, Almog S
and Gak E: A coding VKORC1 Asp36Tyr polymorphism predisposes to
warfarin resistance. Blood. 109:2477–2480. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mahmoudi E and Cairns MJ: MiR-137: An
important player in neural development and neoplastic
transformation. Mol Psychiatry. 22:44–55. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Neault M, Mallette FA and Richard S:
miR-137 modulates a tumor suppressor network-inducing senescence in
pancreatic cancer cells. Cell Rep. 14:1966–1978. 2016. View Article : Google Scholar : PubMed/NCBI
|
